News

Revenues increased in the fourth quarter by four percent to 61.8 (59.6) and EBIT increased by 60 percent to 8.8 MSEK (5.5). Profitability was positively affected by currency effects. For the full year 2022, sales grew by 76 percent, out of which 16 percent in organic growth. Operating profit increased to 32.4 MSEK (20.1). In the fourth quarter, business unit Surgical Table sales declined by four percent...

Stille AB reports that Torbjörn Sköld, incoming CEO starting March 20th, 2023, purchased 8,770 shares in Stille on January 31st, 2023. The shares were purchased at 114 SEK per share, with a total value of 997,780 SEK. Torshälla, February 2nd, 2023. For more information, please contact: Niklas Carlén Interim CEO and President +46 (0)73 087 49 70 | niklas.carlen@stille.se Stille...

Torbjörn Sköld will begin his tenure as new Stille’s new CEO on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company’s CEO since April 1st, 2019. Stille’s board of directors have decided to appoint Niklas Carlén as Interim CEO up until Torbjörn will commence his employment. Niklas has been the company’s CFO since June...

Torbjörn will begin his tenure on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company’s CEO since April 1st, 2019. Torbjörn comes most recently from De Puy Synthes EMEA, a Johnson & Johnson company, where he has been Vice President. Lars Kvarnhem, chairman of the board comments today’s announcement: “First, I would like to thank Hanna...

Revenues increased by 17 percent to 59.6 MSEK (51.1). Operating profit increased by 32 percent to 7.2 MSEK (5.5). Positive currency effects of 2.7 MSEK affected the result after financial items. Revenues for Surgical Instruments increased by six percent to 30.1 MSEK (28.4). Profitability was affected by an unfavorable product and geographic market mix. Surgical Table-revenues grew by 30 percent to...

Revenues increased by 56 percent to 63.3 MSEK (40.6) and the organic growth amounted to 14 percent with revenues of 46.1 MSEK. Operating profit increased by 72 percent 8.9 MSEK (5.2). Compared to the same quarter last year, business unit Surgical Instruments doubled its revenue driven by the acquired volume of S&T. For the same period, business unit Surgical Tables increased sales by 25 percent...

Revenues for the first quarter increased by 72 percent to 61.6 MSEK (35.8) and the organic growth amounted to 21 percent with revenues of 43.3 MSEK. Operating profit increased to 7.5 MSEK (4.0). ”I can conclude that revenues for business unit Surgical Tables never has been higher than during the first quarter 2022. Most notable is the growth outside the US where sales increased by 52 percent...

Stille’s Annual Report for the business year of 2021 is being published today and can be found on the company website www.stille.se. The Annual Report 2021 can also be found in full as an attachment to this press release. Torshälla, March 31st, 2022. For more information, please contact: Hanna Ernestam Wilkman CEO and President +46 (0)72 402 10 88 | hanna.e.wilkman@stille.se Stille AB...

Revenues for the fourth quarter reached 59.6 MSEK (45.0), including recently acquired S&T whose sales exceeded expectations. Excluding the acquisition sales amounted to 44.0 MSEK despite challenges in the US for both business units. ”To strengthen growth in the US-market, we have in December launched a new general surgery table, GS2®, in an exclusive collaboration with GE Healthcare...

With over 20 years of experience in the market, Synovis Micro Companies Alliance, Inc, a Baxter-owned company, has successfully targeted surgical disciplines that require the finest surgical instrumentation, including the microsurgical, plastics and cardiovascular disciplines. As of January 1st, 2022, Synovis has been appointed the exclusive distributor of Stille’s surgical instruments in the...